摘要
目的:探讨用不同剂量的瑞舒伐他汀对ACS(急性冠状动脉综合征)患者进行治疗对其Hcy(同型半胱氨酸)和Lp-PLA2(脂蛋白磷脂酶A2)水平的影响。方法:选择2016年6月至2017年1月期间在沧州市人民医院心血管内科接受治疗的100例ACS患者作为研究对象。按照随机数表法将这100例患者分为对照组和观察组,每组各有50例患者。对两组患者均进行抗血小板、抑制心室重构及减轻心肌耗氧等常规治疗。在此基础上,为对照组患者使用小剂量(10 mg/d)的瑞舒伐他汀进行治疗,为观察组患者使用大剂量的(20 mg/d)瑞舒伐他汀进行治疗。然后,比较两组患者治疗前后其Hcy的水平、Lp-PLA2的水平及不良反应的发生率。结果:治疗后,两组患者Hcy的水平、Lp-PLA2的水平与治疗前相比均有所降低,且观察组患者Hcy的水平、Lp-PLA2的水平均低于对照组患者,差异有统计学意义(P<0.05)。结论:采用小剂量的瑞舒伐他汀或大剂量的瑞舒伐他汀对ACS患者进行治疗均能够有效地降低其Hcy的水平和Lp-PLA2的水平,从而增加其冠状动脉粥样硬化斑块的稳定性。与采用小剂量的瑞舒伐他汀相比,采用大剂量的瑞舒伐他汀对ACS患者进行治疗的效果更好。
objective： to investigate the effects of different doses of resuvastatin on the levels of Hcy（homocysteine） and lp-pla2（lipoprotein phospholipase A2） in patients with ACS（acute coronary syndrome）. Methods： 100 patients with ACS who received treatment in the department of cardiovascular medicine of cangzhou people＇s hospital from June 2016 to January 2017 were selected as subjects. The 100 patients were divided into the control group and the observation group according to the random number table method, with 50 patients in each group. Antiplatelet, inhibiting ventricular remodeling and reducing myocardial oxygen consumption were performed in both groups. On this basis, the control group was treated with a small dose（10 mg/d） of resuvastatin, and the observation group was treated with a large dose（20 mg/d） of resuvastatin. Then, Hcy level, lp-pla2 level and incidence of adverse reactions were compared between the two groups before and after treatment. Results： after treatment, the levels of Hcy and lp-pla2 in the two groups were lower than those before treatment, and the levels of Hcy and lp-pla2 in the observation group were lower than those in the control group, with statistically significant differences（P〈0.05）. Conclusion： treatment of ACS patients with small doses of rosuvastatin or large doses of rosuvastatin can effectively reduce the levels of Hcy and lp-pla2, thereby increasing the stability of coronary atherosclerotic plaques. Treatment with large doses of resuvastatin was more effective in ACS patients than with low doses of resuvastatin.
作者
赵殿儒
祁景蕊
Zhao Dianru;Qi Jingrui(Cangzhou people＇s hospital,Cangzhou Hebei 061000;Cangzhou central hospital,Cangzhou Hebei 061000)
